U-500 insulin as a component of basal bolus insulin therapy in type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 14, Issue 6, 2012, Pages 505-507

  Lowery, Jolene Brown ^a,c   Donihi, Amy C ^b   Korytkowski, Mary T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; LONG ACTING INSULIN; METFORMIN; PIOGLITAZONE; SHORT ACTING INSULIN; U 500 INSULIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BASAL BOLUS INSULIN; BOLUS INJECTION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN TREATMENT; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT RESPONSE; WEIGHT GAIN;

BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES; WEIGHT GAIN;

EID: 84861976663     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0248     Document Type: Article

References (10)

1. Crasto W, Jarvis J, Hackett E, Nayyar V, McNally PG, Davies MJ, Lawrence IG: Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgrad Med J 2009;85:219-222.
2. Quinn SL, Lansang C, Mina D: Safety and effectiveness of U-500 insulin therapy in patients with insulin-resistant type 2 diabetes mellitus. Pharmacotherapy 2011;31:695-702.
3. Garg R, Johnston V, McNally PG, Davies MJ, Lawrence IG: U-500 insulin: why, when and how to use in clinical practice. Diabetes Metab Res Rev 2007;23:265-268. (Pubitemid 46851466)
4. Cochran E, Musso C, Gorden P: The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005;28:1240-1244. (Pubitemid 40616647)
5. Lane WS, Weinrib SL, Rappaport JM, Przestrzelski T: A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance. Endocr Pract 2009;16:778-784.
6. Garg R, Johnston V, McNally PG, Davies MJ, Lawrence IG: Practical aspects in the usage of U-500 insulin. Pract Diabetes Int 2006;23:118-121. (Pubitemid 44755509)
7. Ballani P, Tran MT, Navar MD, Davidson MB: Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. Diabetes Care 2006;29:2504-2505. (Pubitemid 44912260)
8. Davidson MB, Navar MD, Echeverry D, Duran P: U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care 2010;33:281-283.
9. Wafa WS, Khan MI: Use of U-500 regular insulin in type 2 diabetes. Diabetes Care 2006;29:2175-2176. (Pubitemid 44871206)
10. Lane WS, Cochran EK, Jackson JA, Scism-Bacon JL, Corey IB, Hirsch IB, Skyler JS: High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract 2009;15:71-79.